Intimation Of Board Meeting Regarding Financial Result For The Quarter Ended On June 30, 2017
Intimation of Board Meeting regarding Financial Result for the Quarter Ended on June 30, 2017 scheduled to be held on Thursday, September 14, 2017. Publication Of Notice Of Annual General Meeting In Newspaper
Pursuant to regulation 47 of SEBI (LODR) Regulations, 2015 please find enclosed herewith notice published in newspapers (Gujarati & English edition) informing members of the Company regarding 23rd Annual General Meeting of the Company. Shareholding for the Period Ended June 30, 2017
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended On June 30, 2017
Report on Investor Complaints for the Quarter Ended on June 30, 2017 of the Company Board recommends Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2017, inter alia, has recommended the Dividend of Rs. 1.20 (@ 12%) per Share of Face Value of Rs. 10/- each of the Company, subject to the approval of Shareholders at the Annual General Meeting. Outcome of Board Meeting
Outcome of Board Meeting to Consider Financial Result for the period of 31st March, 2017 Financial Result For The Quarter And Year Ended On 31St March, 2017
The Board of Directors of the Company at their meeting held on May 30, 2017 had considered following: Approved the Audited Consolidated and Standalone Financial Results along with Statement of Assets and Liabilities of the Company for the Quarter and Year Ended on 31st March, 2017. Auditors' Report on Audited Consolidated and Standalone Financial Results for the aforesaid period received from Statutory Auditors M/s. J. T. Shah & Co.... Board to consider Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 30, 2017, inter alia, to consider the following businesses:1. Approval and adoption of Audited Consolidated and Standalone Financial results of the Company for the Quarter and Year ended on March 31, 2017.... Closure of Trading Window
The trading window will remain close for the Promoters, Directors, Insiders, Designated Persons and the Connected Persons from the date of this letter and shall reopen after the expiry of 48 hours from the time the result becomes generally available.